Abstract:
:Over the last decades, a better understanding of breast cancer heterogeneity provided tools for a biologically based personalization of anticancer treatments. In particular, the overexpression of the human epidermal growth factor receptor 2 (HER2) by tumor cells provided a specific target in these HER2-positive tumors. The development of the monoclonal antibody trastuzumab, and its approval in 1998 for the treatment of patients with metastatic disease, radically changed the natural history of this aggressive subtype of breast cancer. These findings provided strong support for the continuous research in targeting the HER2 pathway and implementing the development of new anti-HER2 targeted agents. Besides trastuzumab, a series of other anti-HER2 agents have been developed and are currently being explored for the treatment of breast cancer patients, including those diagnosed with early-stage disease. Among these agents, neratinib, an oral tyrosine kinase inhibitor that irreversibly inhibits HER1, HER2, and HER4 at the intracellular level, has shown promising results, including when administered to patients previously exposed to trastuzumab-based treatment. This article aims to review the available data on the role of the HER2 pathway in breast cancer and on the different targeted agents that have been studied or are currently under development for the treatment of patients with early-stage HER2-positive disease with a particular focus on neratinib.
journal_name
Onco Targets Therjournal_title
OncoTargets and therapyauthors
Kourie HR,El Rassy E,Clatot F,de Azambuja E,Lambertini Mdoi
10.2147/OTT.S122397subject
Has Abstractpub_date
2017-07-10 00:00:00pages
3363-3372issn
1178-6930pii
ott-10-3363journal_volume
10pub_type
杂志文章,评审abstract::Two decades ago, lymphatic mapping of sentinel lymph nodes (SLN) was introduced into surgical cancer management and was termed sentinel node navigated surgery. Although this technique is now routinely performed in the management of breast cancer and malignant melanoma, it is still under investigation for use in other ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S50394
更新日期:2014-06-24 00:00:00
abstract:Purpose:Breast cancer (BC) is the most common cancer in women. Emerging evidence has demonstrated that lncRNAs play an important role in BC. The objective of this study was to investigate the impact of the long non-coding RNA (lncRNA), H19/miRNA-130a-3P/special AT-rich sequence-binding protein-1 (SATB1) axis on BC prog...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S280142
更新日期:2020-12-07 00:00:00
abstract:BACKGROUND:The purpose of this study was to determine the efficacy of sorafenib in preventing and treating tumor recurrence after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria. METHODS:Thirty patients with primary hepatic carcinoma exceeding the Milan criteria underwent ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S31387
更新日期:2012-01-01 00:00:00
abstract:Background:miRNA expression acts as a potential biomarker in many diseases including endometrial carcinoma (EC). miR-486-5p dysregulation is observed in several tumor types, but the roles of miR-486-5p in EC are hardly ever studied. Objective:This study aimed to analyze the expression profile of miR-486-5p in tumor ti...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S246841
更新日期:2020-05-28 00:00:00
abstract::The study aimed to investigate the difference of setup errors on different registration in the treatment of nasopharyngeal carcinoma based on weekly cone-beam computed tomography (CBCT). Thirty nasopharyngeal cancer patients scheduled to undergo intensity-modulated radiotherapy (IMRT) were prospectively enrolled in th...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S87159
更新日期:2015-09-14 00:00:00
abstract:Purpose:As a novel type of non-coding RNAs, circRNAs were found to play important roles in cancer progression. In this study, we aim to investigate genome-wide circRNAs expression and potential functions in glioma to find new therapeutic targets for glioma treatment. Patients and Methods:A total of 92 pairs of glioma ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S241347
更新日期:2020-04-01 00:00:00
abstract:Background:Although there have been great advances in mechanisms and therapeutic methods of prostate cancer, the mortality rate of prostate cancer remains high. The castration-resistant prostate cancer (CRPC), which develops from hormone-sensitive prostate cancer, foreshadows a more dismal outcome. Concomitant with the...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S159777
更新日期:2018-05-28 00:00:00
abstract:PURPOSE:This study aimed to spare hematopoietical bone marrow (BM) identified by magnetic resonance (MR) radiation in order to alleviate acute hematologic toxicity (HT) for gastric cancer patients treated with postoperative chemoradiotherapy (CRT). METHODS:A prospective, open-label, single-arm Phase II study (Clinical...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S91586
更新日期:2016-05-05 00:00:00
abstract::The aim of this study was to investigate the clinical characteristics and efficacy of chronic myeloid leukemia (CML) onset with extreme thrombocytosis. A total of 121 newly diagnosed and untreated CML patients in chronic phase with complete clinical information from the First Hospital of Jilin University, from January...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S142587
更新日期:2017-07-17 00:00:00
abstract:Introduction:Ribosome binding protein 1 (RRBP1) is reported to be correlated with tumor formation and progression. However, the role of RRBP1 in bladder cancer is unclear. In this study, we aimed to investigate the expression of RRBP1 and its influence on cell proliferation in bladder cancer. Methods:Quantification re...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S252043
更新日期:2020-07-07 00:00:00
abstract::Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for ~10% and 2%-3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are refractory or relapse after first-line therapy, and elderly patients with HL represent a subgroup of patients with suboptimal responses to the c...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S141053
更新日期:2018-08-06 00:00:00
abstract:Introduction:Gastric cancer (GC) is one of the most malignancies leading to human mortality due to its development, progress, metastasis and poor prognosis, despite the development of remarkable chemotherapy and surgery. The 5-fluorouracil (5-Fu) is an effective anti-gastric cancer agent. However, a fraction of GC patie...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S230875
更新日期:2020-07-01 00:00:00
abstract::Orbital metastasis as the initial presentation of lung adenocarcinoma is very rare, and so the lack of knowledge about this phenomenon can easily result in misdiagnosis, either as a orbital primary tumor or benign lesion. Here, we report a rare case in which the orbital symptom appeared first without any pulmonary man...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S99583
更新日期:2016-05-09 00:00:00
abstract::In the absence of a driver mutation, chemotherapy is the standard treatment option as first- and second-line therapy for advanced non-small-cell lung cancer (NSCLC). Though a large number of patients are suitable for post second-line therapies, the quality and quantity of the available drugs in this setting is poor. A...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S126613
更新日期:2017-01-18 00:00:00
abstract:Background:The immune environment of lung cancer is complex, and the critical immune factors that promote lung cancer progression need to be explored. Granulocytic myeloid-derived suppressor cells (G-MDSCs) are regarded as immune suppressing cells. However, they also promote tumor progression through other ways, which ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S256378
更新日期:2020-09-30 00:00:00
abstract::Preclinical studies have demonstrated that Apatinib, major targeting vascular endothelial growth factor receptor-2 (VEGFR-2), could inhibit the proliferation of anaplastic thyroid carcinoma (ATC) cells in vitro and in vivo. The efficacy and safety in ATC patients, however, remains unknown. Here, we report the case of ...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S223727
更新日期:2019-12-02 00:00:00
abstract::Intracranial myeloid sarcoma is a very rare disease with poor prognosis. We report a case of a 28-year-old male patient who was admitted with intense headache, vision disturbance and severe vomiting in June 2017. He had a history of neurosurgical tumor resection operation in April 2017, and the pathological diagnosis ...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S230478
更新日期:2020-01-09 00:00:00
abstract:Background:Growing evidence suggests that miR-150 plays an inhibitory role in various types of cancer. However, the function and underlying mechanisms of miR-150 in triple-negative breast cancer (TNBC) remain unknown. Patients and methods:miR-150 expression was detected by qRT-PCR and ISH in TNBC tumor and adjacent no...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S161996
更新日期:2018-04-24 00:00:00
abstract::The clinicopathological and prognostic significance of telomerase reverse transcriptase (TERT) promoter mutations have been widely investigated in thyroid cancer; however, the results are still discrepant. Systematic searches were performed in PubMed, Web of Science, Scopus, Ovid, and the Cochran Library databases for...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S116594
更新日期:2016-11-11 00:00:00
abstract:BACKGROUND:Primary angiosarcoma of breast (PAOB) is a rare and highly aggressive malignancy. There is no general agreement on optimal treatments or prognostic factors for this orphan disease. The objective of this study was to investigate the clinicopathologic features and management experiences of PAOB. METHODS:We pe...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S92769
更新日期:2015-11-04 00:00:00
abstract:Background:A biosynthetic ginsenoside, 3-O-β-D-glucopyranosyl-12-O-β-D-glucopyranosyl-dammar-24-ene-3β, 12β, 20S-triol (C3C12PPD), showed antitumor activity against many tumor cells in vitro, especially had better anti-lung cancer activity than Rg3 in vitro and in vivo. However, the effects and molecular mechanisms of ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S217039
更新日期:2019-09-09 00:00:00
abstract:Background:Large amounts of researches indicate that non-coding RNAs play a crucial role in many malignancies. However, the potential mechanisms of non-coding RNAs involved in osteosarcoma tumorigenesis remain elusive. Materials and Methods:The expression of long non-protein coding RNA 691 (lncRNA 691) in cell lines a...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S249827
更新日期:2020-05-22 00:00:00
abstract:Purpose:B7 homologue 6 (B7-H6) has been found at an up-regulated level in multiple cancer cells and identified to be positively correlated with inferior clinical features. In non-Hodgkin lymphoma (NHL), however, the roles of B7-H6 and the underlying mechanism of action remain unclear. Through in vivo and in vitro exper...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S257512
更新日期:2020-06-18 00:00:00
abstract:Purpose:Here, we investigated the involvement of the miR-188-5p/inhibitor of the DNA binding 4 (ID4) axis in retinoblastoma (Rb). Patients and methods:We included 35 Rb tissues and the corresponding adjacent normal tissues. RT-qPCR, Western blot, lentivirus transfection, measurement of cell migration in vitro, and chi...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S229739
更新日期:2019-11-27 00:00:00
abstract:PURPOSE:Randomized trials showing a clear survival benefit of intensity-modulated radiotherapy (IMRT) over 3-dimensional conformal radiotherapy (3D-CRT) in the treatment of lung cancer are lacking. This study compared the survival rates of patients with stage III non-small cell lung cancer who were treated with either ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S124311
更新日期:2016-11-24 00:00:00
abstract::During the past decade, immunotherapy targeting immune checkpoints has become an important component of the treatment paradigm for numerous malignancies, especially PD-1/PD-L1 blockade which was demonstrated to rejuvenate disabled T cells in cancer patients to achieve long-term remissions. However, the clinical outcom...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S221340
更新日期:2019-10-15 00:00:00
abstract:Objective:As an epidermal growth factor, receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib demonstrates a good therapeutic effect in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). However, an overwhelming majority of these patients inevitably develop resistance against gefitinib. Unfortunately, th...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S220462
更新日期:2019-11-18 00:00:00
abstract:Introduction:Dynamin 3 (DNM3) is a large GTPase that possesses mechanochemical properties and has been shown to be involved in malignancies. However, most studies about DNM3 are observational, and knowledge of the precise molecular mechanism of DNM3 remains limited. Materials and methods:We constructed a PCDH-CMV-MCS-...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S176388
更新日期:2018-10-09 00:00:00
abstract:Background:It was previously reported that downregulation of miR-218 promoted thyroid cancer cell invasion, migration, and proliferation. However, the biological functions of miR-218 and its possible regulatory mechanisms in papillary thyroid cancer (PTC) cells are still elusive. Materials and methods:The expression l...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S172152
更新日期:2018-09-28 00:00:00
abstract::Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S84153
更新日期:2016-07-25 00:00:00